PRF1 and neoplasm: Also, bortezomib treatment in mice influenced tumor microenvironment by increasing the levels of immunostimulatory cytokines IL-2, IL-12 and IL-15 (12) and enhanced the production of IFNγ and expression of effector molecules perforin, granzyme B and FasL in CD8+ T cells (13, 14).